<DOC>
	<DOCNO>NCT02412878</DOCNO>
	<brief_summary>The purpose study compare once-weekly carfilzomib dose combination dexamethasone twice-weekly carfilzomib dose combination dexamethasone subject relapse refractory multiple myeloma , previously treat bortezomib immunomodulatory agent ( IMiD ) .</brief_summary>
	<brief_title>A Study Subjects With Relapsed Refractory Multiple Myeloma Receiving Carfilzomib Combination With Dexamethasone , Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing ( ARROW )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Key 1 . Relapsed multiple myeloma 2 . Refractory multiple myeloma define meet 1 following : Nonresponsive recent therapy ( stable disease PD treatment ) , Disease progression within 60 day discontinuation recent therapy 3 . At least 2 3 prior therapy multiple myeloma 4 . Prior exposure immunomodulatory agent ( IMiD ) 5 . Prior exposure proteasome inhibitor ( PI ) 6 . Documented response least partial response ( PR ) 1 line prior therapy 7 . Measurable disease least 1 follow assess within 21 day prior randomization : Serum Mprotein ≥ 0.5 g/dL Urine Mprotein ≥ 200 mg/24 hour In subject without detectable serum urine Mprotein , serum free light chain ( SFLC ) &gt; 100 mg/L ( involved light chain ) abnormal serum kappa lambda ratio 8 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 1 9 . Left ventricular ejection fraction ( LVEF ) ≥ 40 % within 21 day prior randomization 10 . Adequate organ bone marrow function within 21 day prior randomization define : Bilirubin &lt; 1.5 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3 time ULN Absolute neutrophil count ( ANC ) ≥ 1000/mm3 ( screen ANC independent growth factor support ≥ 1 week ) Hemoglobin ≥ 8.0 g/dL ( Use erythropoietic stimulating factor red blood cell [ RBC ] transfusion per institutional guideline allow , however recent RBC transfusion may do within 7 day prior obtain screen hemoglobin . ) Platelet count ≥ 50,000/mm3 ( ≥ 30,000/mm3 myeloma involvement bone marrow &gt; 50 % . Subjects received platelet transfusion least 1 week prior obtain screen platelet count . ) Calculated measured creatinine clearance ( CrCl ) ≥ 30 mL/min Key 1 . Waldenström macroglobulinemia 2 . Multiple myeloma Immunoglobin M ( IgM ) subtype 3 . POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) 4 . Plasma cell leukemia ( &gt; 2.0 × 109/L circulate plasma cell standard differential ) 5 . Myelodysplastic syndrome 6 . Second malignancy within past 5 year except : Adequately treat basal cell squamous cell skin cancer Carcinoma situ cervix Prostate cancer &lt; Gleason score 6 stable prostatespecific antigen ( PSA ) 12 month Ductal breast carcinoma situ full surgical resection ( i.e. , negative margin ) Treated medullary papillary thyroid cancer Similar condition expectation &gt; 95 % fiveyear diseasefree survival 7 . History current amyloidosis 8 . Cytotoxic chemotherapy within 28 day prior randomization 9 . Immunotherapy within 21 day prior randomization 10 . Glucocorticoid therapy within 14 day prior randomization exceeds cumulative dose 160 mg dexamethasone 1000 mg prednisone 11 . Radiation therapy : Focal therapy within 7 day prior randomization Extended field therapy within 21 day prior randomization 12 . Prior treatment either carfilzomib oprozomib 13 . Known history allergy Captisol ( cyclodextrin derivative use solubilize carfilzomib ) 14 . Contraindication dexamethasone require concomitant drug supportive treatment , include hypersensitivity antiviral drug , intolerance hydration due preexist pulmonary cardiac impairment 15 . Active congestive heart failure ( New York Heart Association [ NYHA ] Class III IV , refer Appendix F ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention , acute diffuse infiltrative pulmonary disease , pericardial disease , myocardial infarction within 6 month prior enrollment 16 . Active infection within 14 day prior randomization require systemic antibiotic 17 . Pleural effusion require thoracentesis within 14 day prior randomization 18 . Ascites require paracentesis within 14 day prior randomization 19 . Ongoing graftversushost disease 20 . Uncontrolled hypertension uncontrolled diabetes despite medication 21 . Significant neuropathy ( ≥ Grade 3 ) within 14 day prior randomization 22 . Known cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>